Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

James Irwin

Clinical Cardiac Electrophysiology Lutz, FL Medical Doctor

NPI 1669418901 CMS profile 257178

16105 N Florida Ave Ste E, Lutz, FL 33549

Open in the dashboard

General payments

$17,450

251 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$497,084 paid to institutions, not to them · program years 2019–2025

Through program year 2025, James Irwin of Lutz, FL is reported in the CMS Open Payments database as having received $17,450 across 251 general payments and $0 in research payments paid to them. Separately, studies naming them as principal investigator received $497,084 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 48th percentile of Clinical Cardiac Electrophysiology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,040 16
2024 General $1,189 29
2023 General $2,499 49
2022 General $3,645 40
2021 General $504 9
2020 General $1,089 22
2019 General $7,484 86

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • James Irwin
  • Clinical Cardiac Electrophysiology median
  • Middle half of Clinical Cardiac Electrophysiology
  • National median

In program year 2025, general payments to James Irwin were reported at $1,040. Among 3,064 Clinical Cardiac Electrophysiology profiles paid that year, the median was $2,462 and the middle half received between $733 and $7,710.

Show as a table
Year James Irwin Clinical Cardiac Electrophysiology median Middle half National median
2019 $7,484 $2,361 $585–$8,260 $163
2020 $1,089 $993 $247–$4,351 $114
2021 $504 $1,185 $326–$4,739 $132
2022 $3,645 $2,073 $554–$6,789 $149
2023 $2,499 $2,568 $759–$8,159 $160
2024 $1,189 $2,557 $703–$7,403 $164
2025 $1,040 $2,462 $733–$7,710 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Abbott Laboratories $5,466 56 payments
  2. Boston Scientific Corporation $4,361 34 payments
  3. Medtronic Vascular, Inc. $3,464 31 payments
  4. Medtronic, Inc. $2,308 38 payments
  5. Novartis Pharmaceuticals Corporation $296 18 payments
  6. BioSig Technologies, Inc. $248 1 payment
  7. Biotronik Inc. $200 6 payments
  8. Sanofi-Aventis U.S. LLC $199 15 payments
  9. Pfizer Inc. $148 8 payments
  10. ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) $138 10 payments
  11. Other $622 34 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $6,759 221 payments
  2. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $3,750 13 payments
  3. Consulting Fee $3,675 4 payments
  4. Travel and Lodging $3,253 12 payments
  5. Education $14 1 payment
Products named General payments · program years 2019–2025
  1. Ensite Cardiac Mapping System $4,061 9 payments
  2. Rhythmia Mapping System Diagnostic $3,000 12 payments
  3. Rhythmia Mapping System Rhythmia_EP $811 4 payments
  4. COBALT DR MRI SURESCAN $406 6 payments
  5. Micra $376 12 payments
  6. EVERA MRI XT DR SURESCAN $374 6 payments
  7. AMPLATZER AMULET $252 10 payments
  8. PURE EP SYSTEM $248 1 payment
  9. ENSITE $205 2 payments
  10. ENSITE PRECISION $188 2 payments
  11. Other $3,664 168 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 20 drugs

Part D claims

854

Median for Clinical Cardiac Electrophysiology: 1,090

Drug cost

$261,217

Median for Clinical Cardiac Electrophysiology: $354,841

Branded share of claims

31%

Median for Clinical Cardiac Electrophysiology: 38.3%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Eliquis Apixaban Brand 200 $174,221
Xarelto Rivaroxaban Brand 42 $47,563
Dofetilide Generic 104 $16,811
Entresto Sacubitril/Valsartan Brand 12 $10,063
Repatha Sureclick Evolocumab Brand 11 $6,149
Flecainide Acetate Generic 24 $1,247
Metoprolol Succinate Generic 102 $989
Ezetimibe Generic 32 $813
Midodrine Hcl Generic 16 $669
Irbesartan Generic 47 $461

The 10 drugs with the highest cost, of 20 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 2,573 Part D prescribers listed as Clinical Cardiac Electrophysiology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 65 billing codes

Paid by Medicare

$132,787

Medicare's payments for the services billed

Medicare patients

308

Average age 77

Services billed

1,432

130 women, 178 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Atrial fibrillation 75%
Ischemic heart disease 60%
Arthritis 56%
Heart failure 46%
Chronic kidney disease 42%
Diabetes 41%
COPD 30%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

5 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
Ozempic
  • Novo Nordisk Inc $43
$43 — —
LEQVIO
  • Novartis Pharmaceuticals Corporation $35
$35 — —
ENTRESTO
  • Novartis Pharmaceuticals Corporation $35
$35 12 —
VYNDAQEL
  • PFIZER INC. $20
$20 — —
RYBELSUS
  • Novo Nordisk Inc $10
$10 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

Records

251 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Clinical Cardiac Electrophysiology in Florida

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record